Kelly L. Bolton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelly L. Bolton has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Irenaeus C. C. Chan
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
74 shared publications - Yin Cao
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, USA
68 shared publications - Jie Liu
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
62 shared publications - Duc Tran
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
59 shared publications - Daniel C. Link
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
51 shared publications - Giulia E. M. Petrone
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
50 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (10) , 2579-2589
Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment
- 28 September 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (10) , 2579-2589
Open AccessGermline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment
- Open Access
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk
Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) are two types of clonal hematopoiesis (CH) associated with hematological parameters and malignancy risk. Here we show, in genomic data from 546,090 biobank participants, that co-occurring CH (≥2 CH mutations detected) is present in 1.6% of cancer-free individuals and shows strong evidence for selection (up to 804x enrichment). Co-occurrence is more frequent in those with a prior cancer (3.6%), suggesting treatment-induced selection. Acquisition of CHIP usually precedes mCAs with co-occurrences manifesting stronger phenotypic disruptions in telomere attrition and hematologic parameters than component CH events. Individuals with co-occurring CH have pronounced elevations in risk of myeloid and lymphoid malignancies (HRs>40), particularly when CHIP and mCAs overlap genomically. Our findings indicate CH co-occurrences are selected for in the aging population and identify CH clones with notable implications for future malignancy risk.
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCo-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk
Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) are two types of clonal hematopoiesis (CH) associated with hematological parameters and malignancy risk. Here we show, in genomic data from 546,090 biobank participants, that co-occurring CH (≥2 CH mutations detected) is present in 1.6% of cancer-free individuals and shows strong evidence for selection (up to 804x enrichment). Co-occurrence is more frequent in those with a prior cancer (3.6%), suggesting treatment-induced selection. Acquisition of CHIP usually precedes mCAs with co-occurrences manifesting stronger phenotypic disruptions in telomere attrition and hematologic parameters than component CH events. Individuals with co-occurring CH have pronounced elevations in risk of myeloid and lymphoid malignancies (HRs>40), particularly when CHIP and mCAs overlap genomically. Our findings indicate CH co-occurrences are selected for in the aging population and identify CH clones with notable implications for future malignancy risk.
- Top Cited PapersOpen Access
- 11 March 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (3) , 582-592
CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
Therapy-related myeloid neoplasm (tMN) is a fatal consequence of exposure to cytotoxic therapy administered in the treatment of cancer. Individuals with pre-existing TP53 clonal hematopoiesis (CH) are at high risk of tMN, with avoidance of therapy being the only strategy to reduce tMN risk. Here, in four randomized clinical trials, we show that the CDK4/6 inhibitor trilaciclib, given in conjunction with a variety of chemotherapeutic regimens and across diverse populations of patients with cancer, mitigates chemotherapy-related expansion of CH clones with mutations in DNA damage response genes, including TP53. This finding was also observed in a syngeneic mouse model of TP53-mutant CH, demonstrating that CDK4/6 inhibition blocks platinum-induced TP53 competitive repopulation through promoting hematopoietic stem and progenitor quiescence and decreasing the stemness advantage of TP53-mutant clones. This represents a proof of concept for a potential pharmacologic strategy to block chemotherapy-induced expansion of preleukemic TP53-mutant clones.
- 11 March 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (3) , 582-592
Top Cited PapersOpen AccessCDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
Therapy-related myeloid neoplasm (tMN) is a fatal consequence of exposure to cytotoxic therapy administered in the treatment of cancer. Individuals with pre-existing TP53 clonal hematopoiesis (CH) are at high risk of tMN, with avoidance of therapy being the only strategy to reduce tMN risk. Here, in four randomized clinical trials, we show that the CDK4/6 inhibitor trilaciclib, given in conjunction with a variety of chemotherapeutic regimens and across diverse populations of patients with cancer, mitigates chemotherapy-related expansion of CH clones with mutations in DNA damage response genes, including TP53. This finding was also observed in a syngeneic mouse model of TP53-mutant CH, demonstrating that CDK4/6 inhibition blocks platinum-induced TP53 competitive repopulation through promoting hematopoietic stem and progenitor quiescence and decreasing the stemness advantage of TP53-mutant clones. This represents a proof of concept for a potential pharmacologic strategy to block chemotherapy-induced expansion of preleukemic TP53-mutant clones.
- Open Access
- 5 February 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (5) , 1536-1551
Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies
Clonal hematopoiesis (CH) is defined by the clonal expansion of hematopoietic stem and progenitor cells harboring somatic mutations that confer a fitness advantage. CH is common with advancing age and becomes nearly ubiquitous in middle age. Although typically asymptomatic, CH is associated with an increased risk of hematologic malignancies particularly myeloid neoplasms (MN), diverse non-malignant conditions, and all-cause mortality. Over the past decade, research has provided major insights into the origins of CH. In addition to aging, CH is promoted by environmental exposures, inherited genetic predisposition, and acquired conditions. Large-scale population and longitudinal sequencing studies have identified determinants of clonal behavior. Characterization of the natural history of CH has enabled the development of risk stratification models to identify individuals with CH at high risk for progression to MN, thereby providing a rationale for selecting patient populations best suited for therapeutic intervention trials. Emerging strategies include targeting mutation-specific vulnerabilities, modulating inflammatory pathways, reducing genotoxic therapy-induced clonal selection, and repurposing agents with efficacy in MN. In this review, we summarize current knowledge of the risk factors underlying CH development, highlight recent advances in understanding the determinants of clonal behavior including progression to MN, and discuss emerging therapeutic approaches for preventing malignant transformation and clinical trial design considerations.
- 5 February 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (5) , 1536-1551
Open AccessClonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies
Clonal hematopoiesis (CH) is defined by the clonal expansion of hematopoietic stem and progenitor cells harboring somatic mutations that confer a fitness advantage. CH is common with advancing age and becomes nearly ubiquitous in middle age. Although typically asymptomatic, CH is associated with an increased risk of hematologic malignancies particularly myeloid neoplasms (MN), diverse non-malignant conditions, and all-cause mortality. Over the past decade, research has provided major insights into the origins of CH. In addition to aging, CH is promoted by environmental exposures, inherited genetic predisposition, and acquired conditions. Large-scale population and longitudinal sequencing studies have identified determinants of clonal behavior. Characterization of the natural history of CH has enabled the development of risk stratification models to identify individuals with CH at high risk for progression to MN, thereby providing a rationale for selecting patient populations best suited for therapeutic intervention trials. Emerging strategies include targeting mutation-specific vulnerabilities, modulating inflammatory pathways, reducing genotoxic therapy-induced clonal selection, and repurposing agents with efficacy in MN. In this review, we summarize current knowledge of the risk factors underlying CH development, highlight recent advances in understanding the determinants of clonal behavior including progression to MN, and discuss emerging therapeutic approaches for preventing malignant transformation and clinical trial design considerations.
- Open Access
- 31 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (21) , 5564-5567
Impact of radiotherapy site, modality, and dose on subsequent clonal hematopoiesis
- 31 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (21) , 5564-5567
Open AccessImpact of radiotherapy site, modality, and dose on subsequent clonal hematopoiesis
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Adjusted association between incident CLL and chromosome-specific mCAs by 5 Mb bin within UKBB. Analyses are adjusted for age, age-squared, smoking status (N/F/C), and genetic similarity. Detailed results are given in Supplemental Table 6.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Adjusted association between incident CLL and chromosome-specific mCAs by 5 Mb bin within UKBB. Analyses are adjusted for age, age-squared, smoking status (N/F/C), and genetic similarity. Detailed results are given in Supplemental Table 6.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Tables 1-22 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Supplemental Tables1-22 display descriptive characteristics for both studies and the results of all analyses.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables 1-22 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Supplemental Tables1-22 display descriptive characteristics for both studies and the results of all analyses.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Overlayed density plots for sensitivity analysis removing individuals with total white blood cell count (WBC) above 9.57 × 109 cells/L for absolute risk prediction models of developing CLL for ages 40-80 in UKBB testing set. Models sequentially add demographics, blood cell traits, CLL PGS, and CH to each model. Median and mean of model distributions are in Supplemental Table 21.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Overlayed density plots for sensitivity analysis removing individuals with total white blood cell count (WBC) above 9.57 × 109 cells/L for absolute risk prediction models of developing CLL for ages 40-80 in UKBB testing set. Models sequentially add demographics, blood cell traits, CLL PGS, and CH to each model. Median and mean of model distributions are in Supplemental Table 21.